SCHEMBL3019243

SCHEMBL3019243

O=S(=O)(c1ccc(Cl)c(Cl)c1)C1CCN(c2nc(Cc3cc(Cl)cc(Cl)c3)cs2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
AR P10275 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
RAB9A P51151 1/20 0.34
NFE2L2 Q16236 1/20 0.33
GRM5 P41594 1/20 0.33
HTR7 P34969 2/20 0.33
DNM1L O00429 1/20 0.33
SPR P35270 1/20 0.33
HTR2A P28223 2/20 0.33
HRH3 Q9Y5N1 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2C P28335 1/20 0.32
KCNH2 Q12809 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GHSR Q92847 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009964 0.94 L3MBTL1 (0.35) L3MBTL1LMNAARGAAMAPT
SCHEMBL3017117 0.93 MAPT (0.38) L3MBTL1LMNAARGAAMAPT
SCHEMBL3013801 0.93 L3MBTL1 (0.39) L3MBTL1LMNAARGAAMAPT
SCHEMBL3008157 0.92 HTR2A (0.37) L3MBTL1LMNAGAAMAPTSMN1; SMN2
SCHEMBL3011666 0.91 L3MBTL1 (0.37) L3MBTL1LMNAARMAPTSMN1; SMN2
SCHEMBL3007833 0.91 LMNA (0.37) L3MBTL1LMNAARMAPTSMN1; SMN2
SCHEMBL3015155 0.91 HTR2A (0.41) L3MBTL1LMNAARSMN1; SMN2DNM1L
SCHEMBL3010926 0.91 MAPT (0.40) LMNAGAAMAPTSMN1; SMN2RAB9A
SCHEMBL3009908 0.90 LMNA (0.38) L3MBTL1LMNAARGAAMAPT
SCHEMBL3016860 0.90 L3MBTL1 (0.36) L3MBTL1LMNAARGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885LMNA 80/4885AR 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.